Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-547 in Essential Tremor
NCT02277106Phase 2Completed
- Sponsor
- Sage Therapeutics
- Start
- Sep 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brexanolone in essential tremor (ET) (3 arms), sponsored by Sage Therapeutics. Primary endpoints: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item and 4 more. Started Sep 2014; status: completed.
02
Drugs
brexanolone
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT02277106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277106.